Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective study

被引：47

作者：

Bloemendaal, ALA

Verwaal, VJ

van Ruth, S

Boot, H

Zoetmulder, FAN

机构：

[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, NL-1066 CX Amsterdam, Netherlands

[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Gastroenterol, NL-1066 CX Amsterdam, Netherlands

来源：

EJSO | 2005年 / 31卷 / 10期

关键词：

conventional therapy; peritoneal carcinomatosis; colorectal cancer;

D O I：

10.1016/j.ejso.2005.06.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aims: To report the results of standard therapy for peritonea[ carcinomatosis of collorectal origin, which consists of conventional surgery and systemic chemotherapy. Method: In a prospective study 50 patients with proven peritoneal, carcinomatosis of colorectal origin were treated with conventional surgery combined with 5-fluorouracil and leucovorin, or irinotecan in patients treated by 5-fluorouracil within 12 months prior to entry. Survival and progression-free survival were studied and prognostic factors were analysed. Results: The median survival time was 12.6 months. The median time to progression was 7.6 months. Location of primary tumour and result of conventional surgery and systemic chemotherapy were prognostic factors related to survival. Conclusion: The survival time of patients with peritonea[ carcinomatosis of colorectal origin seems to be increased in patients treated by conventional surgery and systemic chemotherapy when compared to minimal treatment. (C) 2005 Elsevier Ltd. All rights reserved.

引用

页码：1145 / 1151

页数：7

共 31 条

[1]

Beaujard AC, 2000, CANCER-AM CANCER SOC, V88, P2512, DOI 10.1002/1097-0142(20000601)88:11<2512::AID-CNCR12>3.0.CO

[2]

2-J

[3]

Cavaliere F, 2000, J SURG ONCOL, V74, P41, DOI 10.1002/1096-9098(200005)74:1<41::AID-JSO10>3.0.CO

[4]

2-R

[5] MANAGEMENT AND PROGNOSIS OF ADENOCARCINOMA OF THE APPENDIX [J].

CORTINA, R ;

MCCORMICK, J ;

KOLM, P ;

PERRY, RR .

DISEASES OF THE COLON & RECTUM, 1995, 38 (08) :848-852

[6] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[7]

Elias D, 2001, CANCER, V92, P71, DOI 10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO

[8]

2-9

[9]

Elias D M, 2001, Surg Oncol Clin N Am, V10, P915

[10]

Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010

← 1 2 3 4 →